• Users Online: 4039
  • Home
  • Print this page
  • Email this page
Year : 2010  |  Volume : 58  |  Issue : 1  |  Page : 76-78

Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats' disease in children

Department of Pediatric Ophthalmology and Strabismology, Aditya Jyot Eye Hospital Pvt Ltd, Mumbai, India

Correspondence Address:
Shalini Kaul
Department of Pediatric Ophthalmology and Strabismology, Aditya Jyot Eye Hospital Pvt. Ltd, Plot no 153, Road no 9. Major Parmeswaran Road, Wadala, Mumbai - 31
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0301-4738.58480

Rights and Permissions

We describe the role of intravitreal anti-vascular endothelial growth factor (VEGF) agents in Coats' disease in children. In a prospective, interventional, non-randomized case series, three patients (three eyes) aged 16, seven and two years were diagnosed to have Coats' disease. In Case 1 (16 yr/ male) with macular edema, previous laser photocoagulation being unsuccessful, intravitreal pegaptanib sodium (Macugen™) was tried. Case 2 (seven yr/ male) and Case 3 (two yr/ female) were diagnosed to have Stage 4 Coats' and underwent external needle drainage, laser photocoagulation, SF6 gas injection and intravitreal injection of bevacizumab (Avastin™). Reduction of exudation and attached posterior pole (Cases 2 and 3) was seen at a follow-up of six months and two months respectively. Intravitreal anti-VEGF agents may be successfully used as adjunct treatment in select cases of Coats' disease in childhood.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded452    
    Comments [Add]    
    Cited by others 30    

Recommend this journal